NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $1.67 -0.11 (-6.12%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsNews and TrendsOwnershipSEC Filings About Can-Fite BioPharma Stock (NYSE:CANF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$1.60▼$1.7950-Day Range$1.76▼$3.5852-Week Range$1.60▼$12.30Volume814,071 shsAverage Volume909,239 shsMarket Capitalization$1.79 millionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingModerate Buy Company Overview Can-Fite BioPharma Ltd. (NYSE: CANF) is an Israel-based clinical-stage biopharmaceutical company focused on developing small-molecule therapies for inflammatory, metabolic and oncological diseases. The company’s drug candidates are designed to target the A3 adenosine receptor, a receptor involved in regulating inflammatory and immune responses. Can-Fite’s principal programs include piclidenoson (CF101), an orally administered A3 adenosine receptor agonist investigated for conditions such as psoriasis and rheumatoid arthritis, and namodenoson (CF102), a related compound being studied for metabolic dysfunction-associated steatohepatitis and liver cancer. The company has also evaluated its technology in other indications, including certain ophthalmic and inflammatory disorders. Founded in Israel, Can-Fite conducts research and clinical-development activities through operations serving international markets, including the United States and Israel. Its programs are subject to clinical testing and regulatory review, and the company’s therapies have not necessarily received approval for commercial use in every indication studied. Can-Fite was founded and has been led by Dr. Pnina Fishman, who has served as the company’s chief executive officer and has overseen the development of its A3 adenosine receptor platform.AI Generated. May Contain Errors. Read More Can-Fite BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCANF MarketRank™: 1.718855446075 of 5 starsCan-Fite BioPharma scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCan-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCan-Fite BioPharma has a consensus price target of $44.00, representing about 2,465.6% upside from its current price of $1.72.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CANF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Can-Fite BioPharma this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by Institutions21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANF Stock News HeadlinesCan-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026October 26 at 7:00 AM | globenewswire.comCan-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver TransplantationSeptember 9, 2026 | globenewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 26 at 1:00 AM | Weiss Ratings (Ad)Can-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds ExpectationsSeptember 8, 2026 | rttnews.comCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudySeptember 8, 2026 | globenewswire.comCan-Fite BioPharma Announces $4 Million Warrant ExerciseSeptember 2, 2026 | finance.yahoo.comCan-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer StudySeptember 2, 2026 | benzinga.comCan-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsSeptember 2, 2026 | globenewswire.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $4.00 at the beginning of the year. Since then, CANF shares have decreased by 57.1% and is now trading at $1.7150. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) announced its quarterly earnings data on Tuesday, November, 30th. The company reported ($38.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($18.00) by $20.00. The firm had revenue of $0.25 million for the quarter. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma shares reverse split before market open on Monday, January 5th 2026.The 1-20 reverse split was announced on Tuesday, December 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, January 4th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), NIO (NIO), Sorrento Therapeutics (SRNE) and Micron Technology (MU). Company Calendar Last Earnings11/30/2021Today10/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, CANF's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:CANF CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees5Year FoundedN/APrice Target and Rating Average Price Target for Can-Fite BioPharma$44.00 High Price Target$80.00 Low Price Target$8.00 Potential Upside/Downside+2,456.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$405 thousand Price / Sales4.55 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.98Miscellaneous Outstanding Shares1,070,000Free FloatN/AMarket Cap$1.84 million OptionableNot Optionable Beta1.16 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:CANF) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
